Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price rises after strong HY22

The Volpara Health Technologies Ltd (ASX:VHT) share price is rising after the healthcare business released its HY22 result. 

The Volpara Health Technologies Ltd (ASX: VHT) share price is rising after the healthcare business released its HY22 result.

Volpara is a medical technology business which specialises in breast screening for cancer. The business also has a growing exposure to lung cancer screening.

Volpara’s FY22 result

The company reported growth in almost all of its metrics for the first six months of the 2022 financial year.

Total revenue jumped 30% to NZ$12.3 million, which was an increase of 38% if foreign exchange rates hadn’t changed.

Annual recurring revenue (ARR) increased by 59% year on year to US$20.4 million. Its market share continues to grow too. Around 34% of US women have a Volpara product used on their images and data, up from 27% a year ago.

The normalised net loss improved by 4% to NZ$6.4 million and the actual net loss after tax increased 4% to NZ$8.5 million. But the cashflow outflow improved much quicker, rising 30% to NZ$5.5 million.

One of the only metrics that didn’t go up was the gross profit margin, which slightly declined from 91.7% to 91.4%. However, that’s still exceptionally high and not much of a change.

Outlook for Volpara and the share price

Volpara outlined to investors that it has a number of key strategic initiatives at various stages of development.

One is called ‘Analytics in Action’, which is a service designed to help breast imaging facilities develop a culture of continuous performance improvement. This could help grow customer retention and the average revenue per user (ARPU).

It’s also working on ‘Volpara Club’, a digital experience aimed to help customer long-term success, resulting in “retainment, expansion and advocacy”. The goal here is to keep customer retention high, generate upsell and expansion opportunities, and nurture advocates to support new customer acquisition.

The company is looking to expand its electronic health record sales channel. Volpara also wants to build out its data platform, to change the focus from detection to prevention.

Volpara is also waiting for the FDA’s breast density legislation.

Summary thoughts

I think the Volpara share price looks attractive for a long-term investment. The economics and ARPU are heading in the right direction. The partnerships in lung screening could also be a very good long-term move.

In my opinion, it’s one of the ASX growth shares keeping a close eye on.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content